How does Tango Therapeutics (TNGX) make money?

Tango Therapeutics (TNGX) generates revenue primarily from Collaboration Revenue, which accounted for 100% of total revenue in TTM through Q1 2026. The company reported $56.99M in revenue and converted -188.2% of it into net profit, equivalent to roughly −$107.23M in net income — what's left after the cost of revenue, operating expenses, interest, and income taxes.

What is the gross profit margin of Tango Therapeutics (TNGX)?

Tango Therapeutics (TNGX) reported a gross profit margin of 97.3% in TTM through Q1 2026, equivalent to $55.42M in gross profit on $56.99M in revenue. Gross margin measures how much of each dollar of revenue remains after the direct cost of producing or delivering the product — a higher figure typically signals pricing power, scale, or a less capital-intensive business model.

What is the operating profit margin of Tango Therapeutics (TNGX)?

Tango Therapeutics (TNGX) reported an operating profit margin of -206.2% in TTM through Q1 2026, equivalent to −$117.53M in operating income. Operating margin captures profitability after research & development, sales & marketing, and general & administrative expenses — but before interest, taxes, and one-off items — and is the cleanest single read on the underlying business's efficiency.

What is the net profit margin of Tango Therapeutics (TNGX)?

Tango Therapeutics (TNGX) reported a net profit margin of -188.2% in TTM through Q1 2026, equivalent to −$107.23M in net income. Net margin is the bottom-line share of revenue that survives every expense — operating costs, interest, and income taxes — and is the figure that flows directly into earnings per share.

Is Tango Therapeutics (TNGX) profitable?

Tango Therapeutics (TNGX) reported a net loss of $107.23M for TTM through Q1 2026, a net profit margin of -188.2%. Combined operating expenses, interest, and income taxes exceeded revenue, so the period closed in the red on a reported basis.

How much does Tango Therapeutics (TNGX) invest in research and development?

Tango Therapeutics (TNGX) invested $129.35M in research and development during TTM through Q1 2026, roughly 227.0% of total revenue. R&D spending funds the company's future product pipeline and is expensed in full on the income statement rather than capitalised, which makes the operating margin sensitive to how aggressively management chooses to reinvest in innovation.

How much does Tango Therapeutics (TNGX) spend on capital expenditures?

Tango Therapeutics (TNGX) spent $995.00K on capital expenditures (CapEx) during TTM through Q1 2026, roughly 1.7% of total revenue. CapEx represents long-lived investment in property, equipment, data centres, and other physical infrastructure, and is subtracted from operating cash flow to arrive at free cash flow.

How much free cash flow does Tango Therapeutics (TNGX) generate?

Tango Therapeutics (TNGX) generated −$142.54M in free cash flow during TTM through Q1 2026, a free-cash-flow margin of -250.1%. Free cash flow is the cash left after capital expenditures and represents the discretionary pool the company can use to pay dividends, repurchase shares, repay debt, or fund acquisitions without raising external capital.

How Tango Therapeutics Makes Money: 2026 Visual Revenue Map

Tango Therapeutics (TNGX) Income Statement Flow — TTM through Q1 2026

Calculated from the four most recent reported quarters, ending March 31, 2026 (reported May 13, 2026).

Tango Therapeutics discloses geographic revenue only in annual filings. to view the full breakdown.

Frequently asked questions

Data & methodology

Tango Therapeutics (TNGX) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview

TNGX Overview

Counters

Revenue Counter$1.81/s
Earnings Counter−$3.40/s
Economic Scalevs Nauru

Income Statement

How It Makes Money
Income Statement Waterfall
Profit Bridge

Cash Flow

Cash Flow Waterfall
Free Cash Flow Bridge

Capital Return

Buybacks

No dividends or stock splits on record for this company.

Forecast & Valuation

Price Target Scenarios
Fair Value
What If Invested
Stock Seasonality
Daily Price Character47.8% win rate

Tango Therapeutics (TNGX) Income Statement Flow — TTM through Q1 2026

Frequently asked questions

+How does Tango Therapeutics (TNGX) make money?

+What is the gross profit margin of Tango Therapeutics (TNGX)?

+What is the operating profit margin of Tango Therapeutics (TNGX)?

+What is the net profit margin of Tango Therapeutics (TNGX)?

+Is Tango Therapeutics (TNGX) profitable?

+How much does Tango Therapeutics (TNGX) invest in research and development?

+How much does Tango Therapeutics (TNGX) spend on capital expenditures?

+How much free cash flow does Tango Therapeutics (TNGX) generate?

Data & methodology

+What is a Sankey diagram?

+How is the data calculated?

+Where do segment and geographic numbers come from?

+When was this data last updated?

Tango Therapeutics (TNGX) Key Financials

Explore more